Leadership Transition at BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. today confirmed that Jon Stonehouse, the current president and chief executive officer, plans to retire soon, marking the end of an era for the company. As Stonehouse steps down on December 31, 2025, the board has recognized the potential of Charlie Gayer, who currently serves as chief commercial officer, to transition into the role of president effective August 1, 2025, and chief executive officer from January 1, 2026.
Expectations from Charlie Gayer
Gayer's appointment comes on the heels of his successful tenure at BioCryst, where he has significantly impacted the commercial landscape with the launch of ORLADEYO (berotralstat), the first oral prophylactic therapy for hereditary angioedema. Under Gayer's leadership, the company anticipates peak sales for this therapy to reach $1 billion, showcasing his capability to guide BioCryst into its next level of growth.
Successful Drug Launch
Having led the charge on ORLADEYO, Gayer's strong commercial background positions him well for the role of CEO. The launch has not only been a financial success but has also contributed to a paradigm shift in how patients experiencing hereditary angioedema manage their condition. Furthermore, Gayer has played a key role in shaping the company’s strategies, including plans to streamline its operational focus regarding European business ventures.
Recognition of Jon Stonehouse's Contributions
Nancy Hutson, chair of the board, expressed her gratitude for Stonehouse's contributions, stating that he built BioCryst into a profitable firm with a promising future. She noted Gayer's exceptional qualifications during the succession planning process, highlighting his ability to leverage past successes to further enhance the company’s mission to deliver groundbreaking therapies for patients.
Charlie Gayer’s Vision for BioCryst
Gayer acknowledged Stonehouse's impact on fostering a patient-first culture at BioCryst, which has been pivotal to the company's growth. He expressed his excitement about steering the company into its next chapter and reaffirmed his commitment to continuing the legacy established by Stonehouse.
Background and Qualified Experience of Charlie Gayer
Gayer joined BioCryst in 2015, initially as vice president of global strategic marketing, and rapidly advanced to CCO by January 2020. His diverse experience spans over several leadership roles at prestigious firms within the biopharmaceutical sector. Prior to BioCryst, he held significant positions at Talecris Biotherapeutics and Grifols, leading influential marketing strategies focused on rare disease categories, particularly in the treatment of alpha-1 antitrypsin deficiency.
Educational Foundations
Gayer's credentials include a B.A. in Politics from Princeton University and an M.B.A. from Duke University's Fuqua School of Business, underscoring his robust academic foundation that complements his extensive industry experience.
About BioCryst Pharmaceuticals
BioCryst is dedicated to developing innovative treatments for rare diseases using expertise in structure-guided drug design. The firm has successfully commercialized ORLADEYO and is working to advance its pipeline, which includes a variety of therapies. BioCryst remains committed to enhancing the lives of patients inheriting challenging conditions and focuses on delivering first-in-class and best-in-class drug options.
Frequently Asked Questions
Who is Charlie Gayer?
Charlie Gayer is the new chief executive officer of BioCryst Pharmaceuticals, succeeding Jon Stonehouse upon his retirement.
What role did Jon Stonehouse play at BioCryst Pharmaceuticals?
Jon Stonehouse served as the president and chief executive officer, leading the company through significant growth and the commercialization of key therapies such as ORLADEYO.
What is ORLADEYO?
ORLADEYO (berotralstat) is the first oral prophylactic therapy developed for patients with hereditary angioedema, and it has achieved impressive revenue milestones under Gayer's leadership.
What are BioCryst's future plans?
BioCryst aims to expand its therapy pipeline and enhance patient accessibility to innovative treatments, leveraging Gayer's experience and leadership.
How did Gayer's career lead to this position?
Gayer has a strong background in commercial leadership within the biopharmaceutical industry, having successfully launched multiple therapies and shaped strategic initiatives at BioCryst.
